While the changes in tumor biology after EGFR inhibitor treatment and how immunogenic tumors continue to progress after treatment remain unknown, ongoing research is crucial to better understand the role of the EGFR signaling pathway and tumor mutation load in lung tumor cell fate determination and, in turn, help determine appropriate treatment modulation in patients with advanced lung cancer. The gene discussed is EGFR; the disease is lung carcinoma.